Immune Thrombocytopenia Treatment Market
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immune Thrombocytopenia Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Corticosteroids
1.2.3 Intravenous Immunoglobulin (IVIG)
1.2.4 Anti-D Immunoglobulin
1.2.5 Thrombopoietin Receptor Agonist (TPO-RA)
1.2.6 Others
1.3 Market by Application
1.3.1 Global Immune Thrombocytopenia Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals and Clinics
1.3.3 Research and Academic Institutes
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Immune Thrombocytopenia Treatment Market Perspective (2017-2028)
2.2 Immune Thrombocytopenia Treatment Growth Trends by Region
2.2.1 Immune Thrombocytopenia Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Immune Thrombocytopenia Treatment Historic Market Size by Region (2017-2022)
2.2.3 Immune Thrombocytopenia Treatment Forecasted Market Size by Region (2023-2028)
2.3 Immune Thrombocytopenia Treatment Market Dynamics
2.3.1 Immune Thrombocytopenia Treatment Industry Trends
2.3.2 Immune Thrombocytopenia Treatment Market Drivers
2.3.3 Immune Thrombocytopenia Treatment Market Challenges
2.3.4 Immune Thrombocytopenia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Immune Thrombocytopenia Treatment Players by Revenue
3.1.1 Global Top Immune Thrombocytopenia Treatment Players by Revenue (2017-2022)
3.1.2 Global Immune Thrombocytopenia Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Immune Thrombocytopenia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Immune Thrombocytopenia Treatment Revenue
3.4 Global Immune Thrombocytopenia Treatment Market Concentration Ratio
3.4.1 Global Immune Thrombocytopenia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immune Thrombocytopenia Treatment Revenue in 2021
3.5 Immune Thrombocytopenia Treatment Key Players Head office and Area Served
3.6 Key Players Immune Thrombocytopenia Treatment Product Solution and Service
3.7 Date of Enter into Immune Thrombocytopenia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Immune Thrombocytopenia Treatment Breakdown Data by Type
4.1 Global Immune Thrombocytopenia Treatment Historic Market Size by Type (2017-2022)
4.2 Global Immune Thrombocytopenia Treatment Forecasted Market Size by Type (2023-2028)
5 Immune Thrombocytopenia Treatment Breakdown Data by Application
5.1 Global Immune Thrombocytopenia Treatment Historic Market Size by Application (2017-2022)
5.2 Global Immune Thrombocytopenia Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Immune Thrombocytopenia Treatment Market Size (2017-2028)
6.2 North America Immune Thrombocytopenia Treatment Market Size by Type
6.2.1 North America Immune Thrombocytopenia Treatment Market Size by Type (2017-2022)
6.2.2 North America Immune Thrombocytopenia Treatment Market Size by Type (2023-2028)
6.2.3 North America Immune Thrombocytopenia Treatment Market Share by Type (2017-2028)
6.3 North America Immune Thrombocytopenia Treatment Market Size by Application
6.3.1 North America Immune Thrombocytopenia Treatment Market Size by Application (2017-2022)
6.3.2 North America Immune Thrombocytopenia Treatment Market Size by Application (2023-2028)
6.3.3 North America Immune Thrombocytopenia Treatment Market Share by Application (2017-2028)
6.4 North America Immune Thrombocytopenia Treatment Market Size by Country
6.4.1 North America Immune Thrombocytopenia Treatment Market Size by Country (2017-2022)
6.4.2 North America Immune Thrombocytopenia Treatment Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Immune Thrombocytopenia Treatment Market Size (2017-2028)
7.2 Europe Immune Thrombocytopenia Treatment Market Size by Type
7.2.1 Europe Immune Thrombocytopenia Treatment Market Size by Type (2017-2022)
7.2.2 Europe Immune Thrombocytopenia Treatment Market Size by Type (2023-2028)
7.2.3 Europe Immune Thrombocytopenia Treatment Market Share by Type (2017-2028)
7.3 Europe Immune Thrombocytopenia Treatment Market Size by Application
7.3.1 Europe Immune Thrombocytopenia Treatment Market Size by Application (2017-2022)
7.3.2 Europe Immune Thrombocytopenia Treatment Market Size by Application (2023-2028)
7.3.3 Europe Immune Thrombocytopenia Treatment Market Share by Application (2017-2028)
7.4 Europe Immune Thrombocytopenia Treatment Market Size by Country
7.4.1 Europe Immune Thrombocytopenia Treatment Market Size by Country (2017-2022)
7.4.2 Europe Immune Thrombocytopenia Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Immune Thrombocytopenia Treatment Market Size (2017-2028)
8.2 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Type
8.2.1 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Immune Thrombocytopenia Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Application
8.3.1 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Immune Thrombocytopenia Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region
8.4.1 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Immune Thrombocytopenia Treatment Market Size (2017-2028)
9.2 Latin America Immune Thrombocytopenia Treatment Market Size by Type
9.2.1 Latin America Immune Thrombocytopenia Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Immune Thrombocytopenia Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Immune Thrombocytopenia Treatment Market Share by Type (2017-2028)
9.3 Latin America Immune Thrombocytopenia Treatment Market Size by Application
9.3.1 Latin America Immune Thrombocytopenia Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Immune Thrombocytopenia Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Immune Thrombocytopenia Treatment Market Share by Application (2017-2028)
9.4 Latin America Immune Thrombocytopenia Treatment Market Size by Country
9.4.1 Latin America Immune Thrombocytopenia Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Immune Thrombocytopenia Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Immune Thrombocytopenia Treatment Market Size (2017-2028)
10.2 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Type
10.2.1 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Immune Thrombocytopenia Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Application
10.3.1 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Immune Thrombocytopenia Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country
10.4.1 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 CSL Behring
11.1.1 CSL Behring Company Details
11.1.2 CSL Behring Business Overview
11.1.3 CSL Behring Immune Thrombocytopenia Treatment Introduction
11.1.4 CSL Behring Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
11.1.5 CSL Behring Recent Developments
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Immune Thrombocytopenia Treatment Introduction
11.2.4 Amgen Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
11.2.5 Amgen Recent Developments
11.3 F.Hoffmann-La Roche
11.3.1 F.Hoffmann-La Roche Company Details
11.3.2 F.Hoffmann-La Roche Business Overview
11.3.3 F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Introduction
11.3.4 F.Hoffmann-La Roche Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
11.3.5 F.Hoffmann-La Roche Recent Developments
11.4 Kyowa Hakko Kirin
11.4.1 Kyowa Hakko Kirin Company Details
11.4.2 Kyowa Hakko Kirin Business Overview
11.4.3 Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Introduction
11.4.4 Kyowa Hakko Kirin Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
11.4.5 Kyowa Hakko Kirin Recent Developments
11.5 Rigel Pharmaceuticals
11.5.1 Rigel Pharmaceuticals Company Details
11.5.2 Rigel Pharmaceuticals Business Overview
11.5.3 Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Introduction
11.5.4 Rigel Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
11.5.5 Rigel Pharmaceuticals Recent Developments
11.6 Shionogi
11.6.1 Shionogi Company Details
11.6.2 Shionogi Business Overview
11.6.3 Shionogi Immune Thrombocytopenia Treatment Introduction
11.6.4 Shionogi Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
11.6.5 Shionogi Recent Developments
11.7 Dova Pharmaceuticals
11.7.1 Dova Pharmaceuticals Company Details
11.7.2 Dova Pharmaceuticals Business Overview
11.7.3 Dova Pharmaceuticals Immune Thrombocytopenia Treatment Introduction
11.7.4 Dova Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
11.7.5 Dova Pharmaceuticals Recent Developments
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis Immune Thrombocytopenia Treatment Introduction
11.8.4 Novartis Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
11.8.5 Novartis Recent Developments
11.9 Shire
11.9.1 Shire Company Details
11.9.2 Shire Business Overview
11.9.3 Shire Immune Thrombocytopenia Treatment Introduction
11.9.4 Shire Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
11.9.5 Shire Recent Developments
11.10 Ligand Pharmaceuticals
11.10.1 Ligand Pharmaceuticals Company Details
11.10.2 Ligand Pharmaceuticals Business Overview
11.10.3 Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Introduction
11.10.4 Ligand Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
11.10.5 Ligand Pharmaceuticals Recent Developments
11.11 GSK
11.11.1 GSK Company Details
11.11.2 GSK Business Overview
11.11.3 GSK Immune Thrombocytopenia Treatment Introduction
11.11.4 GSK Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
11.11.5 GSK Recent Developments
11.12 Grifols Biologicals
11.12.1 Grifols Biologicals Company Details
11.12.2 Grifols Biologicals Business Overview
11.12.3 Grifols Biologicals Immune Thrombocytopenia Treatment Introduction
11.12.4 Grifols Biologicals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
11.12.5 Grifols Biologicals Recent Developments
11.13 Jiangsu Hengrui Pharmaceutical
11.13.1 Jiangsu Hengrui Pharmaceutical Company Details
11.13.2 Jiangsu Hengrui Pharmaceutical Business Overview
11.13.3 Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Introduction
11.13.4 Jiangsu Hengrui Pharmaceutical Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
11.13.5 Jiangsu Hengrui Pharmaceutical Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Immune Thrombocytopenia Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Corticosteroids
Table 3. Key Players of Intravenous Immunoglobulin (IVIG)
Table 4. Key Players of Anti-D Immunoglobulin
Table 5. Key Players of Thrombopoietin Receptor Agonist (TPO-RA)
Table 6. Key Players of Others
Table 7. Global Immune Thrombocytopenia Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 8. Global Immune Thrombocytopenia Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Immune Thrombocytopenia Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Immune Thrombocytopenia Treatment Market Share by Region (2017-2022)
Table 11. Global Immune Thrombocytopenia Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Immune Thrombocytopenia Treatment Market Share by Region (2023-2028)
Table 13. Immune Thrombocytopenia Treatment Market Trends
Table 14. Immune Thrombocytopenia Treatment Market Drivers
Table 15. Immune Thrombocytopenia Treatment Market Challenges
Table 16. Immune Thrombocytopenia Treatment Market Restraints
Table 17. Global Immune Thrombocytopenia Treatment Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Immune Thrombocytopenia Treatment Revenue Share by Players (2017-2022)
Table 19. Global Top Immune Thrombocytopenia Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Thrombocytopenia Treatment as of 2021)
Table 20. Ranking of Global Top Immune Thrombocytopenia Treatment Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Immune Thrombocytopenia Treatment Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Immune Thrombocytopenia Treatment Product Solution and Service
Table 24. Date of Enter into Immune Thrombocytopenia Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Immune Thrombocytopenia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Immune Thrombocytopenia Treatment Revenue Market Share by Type (2017-2022)
Table 28. Global Immune Thrombocytopenia Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Immune Thrombocytopenia Treatment Revenue Market Share by Type (2023-2028)
Table 30. Global Immune Thrombocytopenia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Immune Thrombocytopenia Treatment Revenue Share by Application (2017-2022)
Table 32. Global Immune Thrombocytopenia Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Immune Thrombocytopenia Treatment Revenue Share by Application (2023-2028)
Table 34. North America Immune Thrombocytopenia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 35. North America Immune Thrombocytopenia Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 36. North America Immune Thrombocytopenia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 37. North America Immune Thrombocytopenia Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 38. North America Immune Thrombocytopenia Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 39. North America Immune Thrombocytopenia Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 40. Europe Immune Thrombocytopenia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 41. Europe Immune Thrombocytopenia Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 42. Europe Immune Thrombocytopenia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 43. Europe Immune Thrombocytopenia Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 44. Europe Immune Thrombocytopenia Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 45. Europe Immune Thrombocytopenia Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 46. Asia Pacific Immune Thrombocytopenia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 47. Asia Pacific Immune Thrombocytopenia Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 48. Asia Pacific Immune Thrombocytopenia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 49. Asia Pacific Immune Thrombocytopenia Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 50. Asia Pacific Immune Thrombocytopenia Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 51. Asia Pacific Immune Thrombocytopenia Treatment Market Size by Region (2023-2028) & (US$ Million)
Table 52. Latin America Immune Thrombocytopenia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 53. Latin America Immune Thrombocytopenia Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 54. Latin America Immune Thrombocytopenia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 55. Latin America Immune Thrombocytopenia Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 56. Latin America Immune Thrombocytopenia Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 57. Latin America Immune Thrombocytopenia Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Immune Thrombocytopenia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Immune Thrombocytopenia Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Immune Thrombocytopenia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Immune Thrombocytopenia Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 62. Middle East and Africa Immune Thrombocytopenia Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 63. Middle East and Africa Immune Thrombocytopenia Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 64. CSL Behring Company Details
Table 65. CSL Behring Business Overview
Table 66. CSL Behring Immune Thrombocytopenia Treatment Product
Table 67. CSL Behring Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
Table 68. CSL Behring Recent Developments
Table 69. Amgen Company Details
Table 70. Amgen Business Overview
Table 71. Amgen Immune Thrombocytopenia Treatment Product
Table 72. Amgen Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
Table 73. Amgen Recent Developments
Table 74. F.Hoffmann-La Roche Company Details
Table 75. F.Hoffmann-La Roche Business Overview
Table 76. F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Product
Table 77. F.Hoffmann-La Roche Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
Table 78. F.Hoffmann-La Roche Recent Developments
Table 79. Kyowa Hakko Kirin Company Details
Table 80. Kyowa Hakko Kirin Business Overview
Table 81. Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Product
Table 82. Kyowa Hakko Kirin Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
Table 83. Kyowa Hakko Kirin Recent Developments
Table 84. Rigel Pharmaceuticals Company Details
Table 85. Rigel Pharmaceuticals Business Overview
Table 86. Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Product
Table 87. Rigel Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
Table 88. Rigel Pharmaceuticals Recent Developments
Table 89. Shionogi Company Details
Table 90. Shionogi Business Overview
Table 91. Shionogi Immune Thrombocytopenia Treatment Product
Table 92. Shionogi Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
Table 93. Shionogi Recent Developments
Table 94. Dova Pharmaceuticals Company Details
Table 95. Dova Pharmaceuticals Business Overview
Table 96. Dova Pharmaceuticals Immune Thrombocytopenia Treatment Product
Table 97. Dova Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
Table 98. Dova Pharmaceuticals Recent Developments
Table 99. Novartis Company Details
Table 100. Novartis Business Overview
Table 101. Novartis Immune Thrombocytopenia Treatment Product
Table 102. Novartis Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
Table 103. Novartis Recent Developments
Table 104. Shire Company Details
Table 105. Shire Business Overview
Table 106. Shire Immune Thrombocytopenia Treatment Product
Table 107. Shire Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
Table 108. Shire Recent Developments
Table 109. Ligand Pharmaceuticals Company Details
Table 110. Ligand Pharmaceuticals Business Overview
Table 111. Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Product
Table 112. Ligand Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
Table 113. Ligand Pharmaceuticals Recent Developments
Table 114. GSK Company Details
Table 115. GSK Business Overview
Table 116. GSK Immune Thrombocytopenia Treatment Product
Table 117. GSK Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
Table 118. GSK Recent Developments
Table 119. Grifols Biologicals Company Details
Table 120. Grifols Biologicals Business Overview
Table 121. Grifols Biologicals Immune Thrombocytopenia Treatment Product
Table 122. Grifols Biologicals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
Table 123. Grifols Biologicals Recent Developments
Table 124. Jiangsu Hengrui Pharmaceutical Company Details
Table 125. Jiangsu Hengrui Pharmaceutical Business Overview
Table 126. Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Product
Table 127. Jiangsu Hengrui Pharmaceutical Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
Table 128. Jiangsu Hengrui Pharmaceutical Recent Developments
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Immune Thrombocytopenia Treatment Market Share by Type: 2021 VS 2028
Figure 2. Corticosteroids Features
Figure 3. Intravenous Immunoglobulin (IVIG) Features
Figure 4. Anti-D Immunoglobulin Features
Figure 5. Thrombopoietin Receptor Agonist (TPO-RA) Features
Figure 6. Others Features
Figure 7. Global Immune Thrombocytopenia Treatment Market Share by Application: 2021 VS 2028
Figure 8. Hospitals and Clinics Case Studies
Figure 9. Research and Academic Institutes Case Studies
Figure 10. Others Case Studies
Figure 11. Immune Thrombocytopenia Treatment Report Years Considered
Figure 12. Global Immune Thrombocytopenia Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 13. Global Immune Thrombocytopenia Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Immune Thrombocytopenia Treatment Market Share by Region: 2021 VS 2028
Figure 15. Global Immune Thrombocytopenia Treatment Market Share by Players in 2021
Figure 16. Global Top Immune Thrombocytopenia Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Thrombocytopenia Treatment as of 2021)
Figure 17. The Top 10 and 5 Players Market Share by Immune Thrombocytopenia Treatment Revenue in 2021
Figure 18. North America Immune Thrombocytopenia Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 19. North America Immune Thrombocytopenia Treatment Market Size Market Share by Type (2017-2028)
Figure 20. North America Immune Thrombocytopenia Treatment Market Size Market Share by Application (2017-2028)
Figure 21. North America Immune Thrombocytopenia Treatment Market Size Share by Country (2017-2028)
Figure 22. United States Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Canada Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Immune Thrombocytopenia Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 25. Europe Immune Thrombocytopenia Treatment Market Size Market Share by Type (2017-2028)
Figure 26. Europe Immune Thrombocytopenia Treatment Market Size Market Share by Application (2017-2028)
Figure 27. Europe Immune Thrombocytopenia Treatment Market Size Share by Country (2017-2028)
Figure 28. Germany Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. France Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. U.K. Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Italy Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Russia Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Nordic Countries Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Asia-Pacific Immune Thrombocytopenia Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 35. Asia Pacific Immune Thrombocytopenia Treatment Market Size Market Share by Type (2017-2028)
Figure 36. Asia Pacific Immune Thrombocytopenia Treatment Market Size Market Share by Application (2017-2028)
Figure 37. Asia Pacific Immune Thrombocytopenia Treatment Market Size Share by Region (2017-2028)
Figure 38. China Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Japan Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. South Korea Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Southeast Asia Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. India Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Australia Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 44. Latin America Immune Thrombocytopenia Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 45. Latin America Immune Thrombocytopenia Treatment Market Size Market Share by Type (2017-2028)
Figure 46. Latin America Immune Thrombocytopenia Treatment Market Size Market Share by Application (2017-2028)
Figure 47. Latin America Immune Thrombocytopenia Treatment Market Size Share by Country (2017-2028)
Figure 48. Mexico Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Brazil Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 50. Middle East & Africa Immune Thrombocytopenia Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 51. Middle East and Africa Immune Thrombocytopenia Treatment Market Size Market Share by Type (2017-2028)
Figure 52. Middle East and Africa Immune Thrombocytopenia Treatment Market Size Market Share by Application (2017-2028)
Figure 53. Middle East and Africa Immune Thrombocytopenia Treatment Market Size Share by Country (2017-2028)
Figure 54. Turkey Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Saudi Arabia Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. UAE Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 57. CSL Behring Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
Figure 58. Amgen Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
Figure 59. F.Hoffmann-La Roche Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
Figure 60. Kyowa Hakko Kirin Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
Figure 61. Rigel Pharmaceuticals Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
Figure 62. Shionogi Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
Figure 63. Dova Pharmaceuticals Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
Figure 64. Novartis Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
Figure 65. Shire Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
Figure 66. Ligand Pharmaceuticals Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
Figure 67. GSK Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
Figure 68. Grifols Biologicals Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
Figure 69. Jiangsu Hengrui Pharmaceutical Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Industry Market Size
